摘要:
A new thrombolytically active protein is not glycosylated and consists of the following amino acid sequence: ##STR1## or said amino acid sequence with an additional N-terminal methionine. DNA sequences encoding the thrombolytically active, non-glycosylated protein and pharmaceutical compositions containing said protein are also disclosed. The protein possesses particularly favorable properties when used to dissolve blood clots.
摘要:
The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding while demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties.
摘要:
The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding while. demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties.
摘要:
Process for purifying serine proteases from a protein mixture by binding the serine protease to an immobilized polypeptide with the activity of an inhibitor DE-3 from Erythrina caffra, removing unbound components from the protein mixture, detaching the serine protease from the inhibitor and separating the immobilized inhibitor from the soluble serine protease and isolating serine protease which is characterized in that a polypeptide is used as the polypeptide which is the product of a prokaryotic or eukaryotic expression of an exogenous nucleic acid. This inhibitor is distinguished by an improved specific activity and is particularly suitable for the purification of plasminogen activators such as tissue plasminogen activators (t-PA and derivatives).
摘要:
A polypeptide which has the activity of an inhibitor DE-3 from Erythrina caffra and which reversibly and selectively binds serine proteases from a protein mixture is obtainable by culturing prokaryotic or eukaryotic host cells which have been transformed or transfected with a nucleic acid that codes for the said polypeptide in a manner that allows the host cells to express the said polypeptide under suitable nutrient conditions and isolating the said polypeptide, wherein the polypeptide has an amino acid sequence which is functionally analogous to SEQ ID NO:2, has a partial region that is more than 85% homologous to the region of amino acids 39-139 of this sequence, has two disulfide bridges and begins N-terminally with SEQ ID NO:4 or with a SEQ ID NO:4 extended N-terminally by methionine and has a binding capacity for tissue plasminogen activators of 1.25 MU/ml and more and is particularly suitable for purifying plasminogen activators such as tissue plasminogen activators (t-PA and derivatives).
摘要翻译:通过培养原核或真核宿主细胞获得具有来自艾瑞氏菌(Erythrina caffra)的抑制剂DE-3并且可逆地和选择性地结合蛋白质混合物的丝氨酸蛋白酶的多肽,所述原核或真核宿主细胞已经用编码 所述多肽以允许宿主细胞在合适的营养条件下表达所述多肽并分离所述多肽的方式,其中所述多肽具有功能上类似于SEQ ID NO:2的氨基酸序列,其部分区域是 与该序列的氨基酸39-139的区域同源超过85%具有两个二硫键,并与SEQ ID NO:4进行N-末端或与蛋氨酸N-末端扩增的SEQ ID NO:4,并具有 组织纤溶酶原激活剂的结合能力为1.25 MU / ml以上,特别适用于纯化纤溶酶原激活剂如组织纤溶酶原激活剂(t-PA和de rivatives)。
摘要:
The invention is a pharmaceutical composition containing a glycosylated protein having human tissue type plasminogen activator activity of at least 1.4 MU/ml, citrate, and at least one of a number of various compounds. The composition has a pH ranging from 4.5 to 9.
摘要:
The invention relates to pharmaceutical preparations containing plasminogen activators, sugars and tranexamic acid, in the form of a lyophilisate or an injection or infusion solution. In particular, the preparations contain a sugar, phosphate buffer, tranexamic acid as well as a surfactant and the liquid solutions preferably have a pH value of 5.5-6.5.
摘要:
Pharmaceutical preparation of a protein with t-PA activity with an enzymatic activity of at least 0.25 MU/ml. and a pH value of 4.5 to 9 which contains a substance of the group citric acid, ascorbic acid, 2-oxoglutaric acid, fumaric acid, Tris and EDTA in a concentration of at least 0.2 mole/l., as well as a medicament based on a protein with t-PA activity and processes for its preparation.
摘要:
Pharmaceutical compositions containing non-glycosylated human tissue type plasminogen activator (t-PA) having enzymatic activity of at least 0.1 MU/ml are disclosed. The compositions have a pH of from 4.5 to 6, contain citrate, and at least one other compound.
摘要:
Stabilized compositions containing a non-glycosylated human tissue type plasminogen activator derivative are disclosed. The derivative is referred to as K2P pro. The composition has enzymatic activity of at least 1.1 mU/ml, a pH of from 4.5 to 6.5, and contains citrate as well as at least one of a variety of different compounds.